Epclusa® (velpatasvir/sofosbuvir) and Harvoni® (ledipasvir/sofosbuvir) – First-time generics
In January 2019, Asegua Therapeutics, a subsidiary of Gilead Sciences, launched authorized generic versions of Gilead’s Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) tablets. Generic Epclusa was launched January 7, 2019 and generic Harvoni will launch late January.
Top